Omeros (NASDAQ:OMER) Upgraded to Hold at StockNews.com

Omeros (NASDAQ:OMER) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

OMER has been the topic of several other research reports. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Tuesday. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Stock Performance

Shares of OMER stock traded down $0.31 during trading hours on Tuesday, reaching $7.91. The company had a trading volume of 1,877,015 shares, compared to its average volume of 545,573. The stock’s fifty day simple moving average is $8.64 and its 200 day simple moving average is $7.61. The company has a market capitalization of $458.38 million, a P/E ratio of -3.42 and a beta of 2.03. Omeros has a twelve month low of $2.61 and a twelve month high of $13.60.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in shares of Omeros by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after purchasing an additional 6,839 shares in the last quarter. State Street Corp raised its stake in Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after buying an additional 3,839 shares in the last quarter. Nomura Holdings Inc. lifted its holdings in Omeros by 136.2% during the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock worth $7,383,000 after buying an additional 430,932 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Omeros by 4.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after buying an additional 18,454 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Omeros by 8.8% in the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock worth $1,610,000 after acquiring an additional 13,201 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.